Dr. Benjamin J. Anderson, MD
Child & Adolescent Psychiatry (Child & Adolescent Psychiatry Physician)
200 Retreat Ave, Hartford Hospital Psychiatry Dept
Hartford, CT 06106
- Medicare participating
At a glance
- Years since graduation
- 14
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 31
Licensed in Connecticut since 2016, according to the Connecticut Department of Public Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Child & Adolescent Psychiatry Physician primary
CT license 055670 (first issued 2016; active) -
Psychiatry Physician
CT license 055670 (first issued 2016; active) · DC license MD043098
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Hartford Hospital Hartford, CT
Medical groups
- Hartford Hospital (1,044 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 31
- Services billed
- 31
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | 14 | 14 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $122,508 in research payments for these studies, mostly to the institutions running them.
- An open label, single arm, extension trial to examine long-term safety of BI 425809 once daily in patients with schizophrenia who have completed previous BI 425809 Phase III trials.(CONNEX-X)
Boehringer Ingelheim Pharmaceuticals, Inc. - A phase III trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophrenia (CONNEX-1)
Boehringer Ingelheim Pharmaceuticals, Inc. - Connex-2
Boehringer Ingelheim Pharmaceuticals, Inc. - Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects
Alkermes, Inc. · Enrolling by invitation · NCT04987229
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.